malaria
repres
global
public
health
problem
hinder
socioeconom
develop
vast
region
world
particularli
tropic
subtrop
area
calcul
peopl
countri
expos
infect
one
plasmodium
speci
estim
clinic
case
lethal
p
falciparum
abund
virul
speci
follow
p
vivax
although
produc
lower
mortal
caus
incapacit
recurr
diseas
plasmodium
vivax
coexist
p
falciparum
vast
zone
planet
preval
region
asia
oceania
latin
america
estim
produc
clinic
case
year
mortal
produc
malaria
higher
africa
mainli
children
younger
five
year
age
pregnant
women
infect
p
falciparum
although
mortal
present
lesser
degre
infect
p
vivax
signific
number
lethal
case
recent
document
hightransmiss
region
like
india
brazil
although
classic
measur
malaria
control
like
earli
diagnosi
time
effici
treatment
mosquito
control
contribut
significantli
reduc
malaria
distribut
map
current
consid
develop
possibl
applic
malaria
vaccin
would
contribut
significantli
costeffect
reduc
impact
malaria
zone
affect
diseas
would
favor
elimin
zone
current
lower
transmiss
last
decad
sever
global
initi
aim
effici
malaria
control
develop
includ
program
denomin
roll
back
malaria
rbm
malaria
elimin
group
meg
recent
malaria
erad
research
agenda
malera
addit
global
fund
gf
sinc
perhap
main
fund
sourc
malaria
control
worldwid
malaria
vaccin
licens
massiv
applic
popul
howev
rise
evid
indic
feasibl
develop
vaccin
firstli
individu
expos
malari
infect
endem
area
natur
acquir
immun
accumul
progress
first
two
decad
life
result
decreas
clinic
sever
diseas
mortal
secondli
experiment
immun
nonimmun
volunt
sporozoit
previous
attenu
irradi
demonstr
individu
vaccin
develop
steril
protect
experiment
infect
thirdli
shown
passiv
transfer
immunoglobulin
immun
adult
naiv
volunt
elimin
circul
parasit
addit
recent
shown
possibl
protect
endem
commun
p
falciparum
least
partial
immun
experiment
vaccin
rt
base
p
falciparum
cs
protein
least
three
level
contempl
plasmodium
cycl
parasit
would
suscept
immunolog
attack
induc
vaccin
preerythrocyt
stage
sporozoit
liver
stage
asexu
erythrocyt
phase
base
capac
stimul
humor
cellular
immun
respons
preerythrocyt
stage
antibodi
inhibit
invas
sporozoit
liver
henc
prevent
hepat
develop
parasit
ulterior
diseas
cytokin
like
produc
cell
would
contribut
halt
intracellular
develop
hepat
schizont
erythrocyt
stage
presenc
antibodi
differ
mechan
prevent
invas
parasit
erythrocyt
also
red
blood
cell
oxygen
radic
destroy
intracellular
parasit
third
level
life
cycl
interrupt
sporogon
phase
occur
intestin
phase
possibl
interrupt
fertil
process
ookinet
invas
intestin
cell
prevent
develop
parasit
within
mosquito
henc
transmiss
suscept
individu
although
vaccin
must
individu
prove
efficaci
consid
essenti
focu
effort
gener
formul
includ
stage
cycl
addit
given
epidemiolog
distribut
malaria
throughout
world
function
vaccin
must
includ
compon
least
two
abund
speci
p
falciparum
p
vivax
accomplish
aim
near
futur
easi
differenti
develop
research
p
falciparum
p
vivax
review
seek
describ
use
highperform
tool
recent
progress
identifi
new
antigen
candid
vaccin
p
falciparum
p
vivax
erythrocyt
preerythrocyt
stage
vaccin
product
inact
live
attenu
dead
organ
employ
develop
sever
vaccin
use
human
function
diseas
like
malaria
due
numer
factor
like
contamin
formul
compon
human
cell
loss
immunogen
difficulti
logist
product
therebi
approach
use
last
two
three
decad
design
malaria
vaccin
base
identifi
subunit
parasit
complet
antigen
fragment
mainli
produc
synthet
peptid
recombin
protein
deriv
sporozoit
merozoit
gametocyt
stage
addit
method
tri
like
product
vaccin
dna
recombin
virus
numer
antigen
particularli
p
falciparum
produc
analyz
preclin
studi
anim
immunogen
lack
toxic
determin
essenti
condit
advanc
clinic
develop
phase
human
process
given
way
current
advanc
protein
test
clinic
preclin
phase
tabl
particular
emphasi
made
p
falciparum
circumsporozoit
cs
protein
reach
maximum
progress
clinic
develop
recent
accomplish
analysi
phase
iii
clinic
studi
vaccin
denomin
pfrt
demonstr
capac
induc
protect
clinic
sever
malaria
african
although
recent
studi
regist
protect
progress
learn
accomplish
analysi
great
valu
homolog
protein
p
vivax
analyz
clinic
trial
phase
current
phase
ii
studi
way
sever
vaccin
reach
clinic
phase
review
avail
literatur
use
express
sequenc
tag
est
technolog
permit
describ
human
genom
genom
multipl
microorgan
biolog
agricultur
archaeolog
medic
interest
vertigin
develop
permit
learn
parasit
plasmodium
genu
genom
compos
gene
avail
genom
p
falciparum
p
vivax
speci
well
progress
bioinformat
genom
proteom
permit
develop
highperform
method
select
clonesynthes
analyz
larg
number
protein
parasit
probabl
acceler
develop
malaria
vaccin
specif
proteom
analys
indic
throughout
life
cycl
least
protein
express
p
falciparum
p
vivax
given
enorm
multipl
protein
becom
evid
clinic
immun
develop
natur
experiment
condit
human
malaria
probabl
induc
multipl
compon
parasit
whose
identif
analysi
possibl
use
highperform
techniqu
result
import
progress
develop
highperform
technolog
emerg
great
promis
term
like
transcriptom
metabolom
lipidom
proteom
increasingli
common
biomed
literatur
expect
follow
year
see
huge
scope
technolog
light
need
analyz
big
volum
inform
produc
one
experi
base
highperform
technolog
recent
numer
tool
develop
inform
analysi
current
facilit
data
mine
effici
develop
complex
studi
employ
omic
technolog
consist
protein
librari
assembl
format
gener
clone
express
larg
fragment
genom
microorgan
case
p
falciparum
p
vivax
avail
simultan
conduct
studi
exampl
reactiv
antibodi
contrast
classic
techniqu
permit
analysi
individu
gene
protein
proteom
technolog
permit
simultan
analysi
immunoreact
profil
hundr
signific
protein
fragment
repres
one
attract
approach
largescal
discoveri
new
vaccin
candid
one
pioneer
laboratori
malaria
proteom
research
led
dr
p
felgner
univers
california
usa
group
develop
highperform
system
protein
express
call
pcr
express
complet
proteom
microorgan
gener
fig
compar
convent
clone
method
plasmid
express
transform
growth
vector
bacteria
pcr
express
offer
variou
advantag
product
transcript
activ
gene
given
use
larg
amount
de
time
requir
intens
labor
seek
simultan
clone
larg
number
gene
differ
lie
pcr
express
base
sound
practic
approach
product
transcript
activ
pcr
fragment
tapf
two
sequenti
pcr
reaction
technic
process
consist
two
stage
first
stage
use
genespecif
primer
amplifi
gene
interest
second
stage
carri
nest
pcr
use
mix
dna
fragment
add
promot
termin
sequenc
fragment
make
tapf
equal
activ
supercoil
plasmid
dna
produc
invitro
invivo
transfect
assay
henc
use
dna
vaccin
dna
vaccin
recombin
virus
contain
plasmodium
protein
insert
previous
describ
tapf
also
quickli
transfer
plasmid
vector
homolog
recombin
offer
highperform
clone
method
requir
use
restrict
enzym
ligat
reaction
tapf
technolog
use
differ
pathogen
evalu
serum
antibodi
titer
peopl
anim
vaccin
infect
natur
identifi
antigen
recogn
immun
system
vaccin
infect
microorgan
base
technolog
reactiv
antigen
select
evalu
differ
kind
studi
eg
immunogen
determin
potenti
vaccin
develop
design
immunediagnost
method
microarray
correspond
microorgan
assess
includ
virus
bacteria
pathogen
parasit
tabl
plasmodium
life
cycl
protein
express
exactli
clear
antigen
mediat
clinic
immun
protec
immun
observ
individu
endem
area
individu
vaccin
parasit
attenu
via
irradi
preliminari
studi
suggest
larg
number
antigen
recogn
immun
system
highlight
import
identifi
repertoir
antigen
epitop
differ
develop
phase
parasit
impli
induct
clinic
immun
recent
highperform
tool
use
identifi
immunodomin
antigen
preliminari
definit
immunoreact
profil
among
group
individu
differ
level
immun
malaria
first
studi
select
panel
p
falciparum
protein
chosen
specif
evalu
immun
respons
volunt
immun
sporozoit
attenu
via
radiat
mainli
hepat
stage
sporozoit
repres
total
genom
clone
express
includ
protein
microarray
reactiv
microarray
evalu
serum
sampl
individu
vaccin
irradi
sporozoit
compar
serum
individu
endem
area
kenya
differ
degre
exposur
malaria
studi
note
subject
natur
expos
malaria
kenya
react
greater
intens
larg
number
antigen
individu
vaccin
irradi
sporozoit
also
among
group
subject
immun
irradi
sporozoit
protect
infecti
challeng
react
greater
intens
higher
number
antigen
unprotect
addit
note
total
protein
highli
reactiv
previous
character
could
repres
potenti
develop
malaria
vaccin
jo
p
falciparum
anoth
studi
held
mali
serum
sampl
individu
rang
age
year
year
observ
averag
number
protein
recogn
individu
expos
infect
increas
age
furthermor
found
reactiv
children
increas
dramat
period
high
transmiss
malaria
contrast
number
protein
recogn
adult
vari
significantli
period
final
analys
provid
inform
pattern
reactiv
p
falciparum
protein
base
phase
life
cycl
protein
express
well
subcellular
locat
proteom
characterist
p
vivax
gene
encod
genom
salvador
sal
strain
assess
recent
protein
preerythrocyt
stage
identifi
wide
recogn
serum
individu
endem
region
colombian
pacif
coast
protein
identifi
panel
antigen
evalu
microarray
current
avail
addit
character
similar
protein
microarray
peptid
microarray
use
function
evalu
protein
peptid
quit
stabl
function
capabl
maintain
activ
reaction
condit
give
advantag
applic
like
microarray
gener
depend
peptid
microarray
prepar
method
classifi
situ
b
synthesi
follow
immobil
name
impli
situ
microarray
synthes
directli
solid
surfac
techniqu
consist
dispens
small
volum
solut
contain
amino
acid
coupl
reagent
design
point
membran
second
case
peptid
previous
synthes
use
convent
equip
method
nanolit
peptid
solut
transfer
solid
surfac
approach
much
effici
peptid
need
synthes
peptid
microarray
use
identifi
ligand
substrat
target
molecul
interest
well
evalu
activ
enzym
protein
bond
peptid
microarray
use
exampl
identifi
epitop
evalu
respons
immun
system
differ
pathogen
use
technolog
wiley
et
al
demonstr
recognit
profil
differ
epitop
p
vivax
protein
chang
en
individu
vaccin
antigen
formul
differ
adjuv
spite
great
valu
massiv
identifi
immunodomin
protein
direct
identif
relev
epitop
repres
high
valuabl
complementari
strategi
mani
epitop
recogn
antibodi
repres
threedimension
surfac
antigen
molecul
precis
interact
bond
surfac
correspond
antibodi
epitop
linear
conform
linear
epitop
form
continu
sequenc
amino
acid
conform
epitop
depend
posit
amino
acid
threedimension
structur
determin
combin
alpha
helix
fold
beta
sheet
coil
structur
shown
doublehelix
structur
contain
abund
epitop
b
cell
proven
target
plasmodium
growth
inhibit
antibodi
pathogen
agent
addit
estim
b
epitop
structur
antibodi
induc
immun
respons
aim
linear
epitop
product
protein
fragment
contain
conform
epitop
great
import
repres
huge
synthesi
technic
challeng
fragment
synthes
protein
need
acquir
stabl
structur
mimic
nativ
structur
henc
recogn
antibodi
challeng
exist
identifi
fragment
protein
sequenc
throughout
genomeproteom
recent
specif
bioinformat
algorithm
develop
select
sequenc
contain
doublehelix
motif
motif
form
stabl
structur
character
presenc
repetit
seven
residu
amino
acid
abcdefg
hydrophob
residu
locat
posit
hydrophil
residu
remain
posit
fig
gener
monomorph
react
antibodi
reactiv
nativ
form
nativ
protein
structur
easili
identifi
bioinformat
tool
significantli
reduc
antigen
select
time
recent
progress
chemic
synthesi
techniqu
permit
product
fragment
amino
acid
length
correspond
p
falciparum
protein
contain
doublehelix
motif
antigen
select
evalu
determin
antigen
use
panel
serum
donor
endem
zone
permit
identifi
new
protein
variabl
length
amino
acid
thereaft
immunogen
fragment
evalu
murin
model
function
assay
conduct
use
specif
antibodi
differ
fragment
demonstr
capac
inhibit
vitro
develop
parasit
antibodydepend
inhibit
trial
adit
also
demonstr
structur
highli
conserv
phase
clinic
trial
current
analyz
fragment
amino
acid
deriv
p
falciparum
protein
select
use
methodolog
addit
immunogen
polypeptid
also
select
methodolog
contain
fragment
three
differ
protein
bound
nonimmunogen
connector
diethylen
glycol
recent
evalu
preclin
trial
technolog
current
use
identifi
p
vivax
antigen
total
peptid
contain
doublehelix
motif
recent
select
protein
p
vivax
erythrocyt
stage
fragment
variabl
length
residu
synthes
use
fmoc
solid
phase
chemistri
use
determin
antigen
compar
reactiv
serum
individu
natur
expos
malaria
hyperendem
area
papua
new
guinea
png
district
maprik
area
medium
low
transmiss
colombia
tumaco
tierralta
gener
higher
reactiv
observ
use
serum
individu
png
total
fragment
preselect
high
reactiv
serum
png
colombia
use
immunogen
assay
mice
larg
number
protein
produc
plasmodium
great
divers
demand
use
highperform
tool
identif
product
analysi
last
decad
import
progress
bioinformat
biotechnolog
permit
construct
microarray
protein
produc
via
recombin
technolog
synthet
peptid
permit
identifi
new
antigen
preerythrocyt
erythrocyt
phase
possibl
function
natur
immun
acquir
p
falciparum
p
vivax
howev
although
progress
permit
studi
effici
respons
profil
antibodi
associ
immun
acquir
natur
vaccin
antigen
immunogen
analys
protein
epitop
select
still
requir
invivo
model
current
scalabl
import
progress
studi
immun
respons
plasmodium
highperform
method
gener
except
condit
identifi
new
vaccin
candid
clinic
develop
